Effectiveness of coenzyme Q10 on learning and memory and synaptic plasticity impairment in an aged Aβ-induced rat model of Alzheimer’s disease: a behavioral, biochemical, and electrophysiological study

Asadbegi, Masoumeh; Komaki, Hamidreza; Faraji, Nafiseh; Taheri, Masoumeh; Safari, Samaneh; Raoufi, Safoura; Kourosh-Arami, Masoumeh; Golipoor, Zoleikha; Komaki‬, Alireza

doi:10.1007/s00213-023-06338-2

Cited by 7 publications

(2 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the most accurate clinical diagnosis of AD, neurochemical data (levels of Aβ1-42, Tau, and pTau181 as well as values of the Aβ1-42/Aβ1-40 ratio) were combined with neuroimaging and neuropsychological tests. The MMSE score (range 0-30) was used to determine dementia severity (AD patients (MMSE: 22 (0-28)), MCI patients (MMSE: 27.5 (26)(27)(28)(29)), and controls (MMSE: 28 (25)(26)(27)(28)(29)(30)). The study was conducted in the Department of Neurodegeneration Diagnostics at the Medical University of Bialystok according to the guidelines of the Declaration of Helsinki; prior to any procedure, every patient signed an informed consent form, and the Bialystok University study (No.…”

Section: Methodsmentioning

confidence: 99%

“…Recent publications showed that GPNMB promotes the polarization of macrophages to the "M2" type, which is described as more protective due to the release of anti-inflammatory cytokines such as IL-10 and TGF-β [21,24,25]. There-fore, GPNMB may possibly act as a factor influencing memory and synaptic plasticity, or working as a neuroprotective agent similar to carotenoids [26], flavonoids [27], coenzyme Q10 [28], or lutein [29].…”

Section: Of 13mentioning

confidence: 99%

See 1 more Smart Citation

Potential Utility of Cerebrospinal Fluid Glycoprotein Nonmetastatic Melanoma Protein B as a Neuroinflammatory Diagnostic Biomarker in Mild Cognitive Impairment and Alzheimer’s Disease

Doroszkiewicz

Kulczyńska-Przybik

Dulewicz

et al. 2023

JCM

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a very common neurodegenerative disorder characterized by the gradual loss of neurons and extracellular amyloid-peptide buildup. There is compelling evidence that the disease process depends on neuroinflammatory alterations, such as the activation of astrocytes and microglia cells. A transmembrane glycoprotein known as glycoprotein nonmetastatic melanoma protein B (GPNMB) plays a neuroprotective role during the development of neurodegeneration. To the best of our knowledge, this is the first investigation discussing the potential clinical usefulness of this protein in the AD continuum, especially in the MCI (mild cognitive impairment) stage. A total of 71 patients with AD or MCI as well as controls were enrolled in this study. The concentrations of GPNMB, YKL-40, Aβ1-42 (amyloid beta 1-42), Tau, and pTau and the Aβ1-42/1-40 ratio in the CSF (cerebrospinal fluid) were tested using immunological methods. The concentrations of both GPNMB and YKL-40 in the cerebrospinal fluid were significantly higher in patients with AD and MCI compared to the controls. Moreover, both proteins were biochemically associated with classical biomarkers of AD and were especially associated with the Aβ1-42/1-40 ratio and Tau and pTau levels in the whole study group. Elevated concentrations of GPNMB were observed in the Aβ(+) group of AD patients compared to the Aβ(−) subjects. Additionally, the diagnostic performance (AUC value) of GPNMB was higher than that of amyloid β1-42 in MCI patients compared with controls. Our study indicates that GPNMB might be a promising neuroinflammatory biomarker for the early diagnosis and prognosis of the AD continuum, with potential utility as a therapeutic target.

show abstract